These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19398956)

  • 1. Early and delayed castrations confer a similar survival advantage in TRAMP mice.
    Zhang ZX; Xu QQ; Huang XB; Zhu JC; Wang XF
    Asian J Androl; 2009 May; 11(3):291-7. PubMed ID: 19398956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of early versus delayed castration targeting androgen on prolonging survival in a mouse model of bladder cancer.
    Zhang Z; Xu Q; Huang X; Yang J; Xu Y; Zhang G
    Int J Clin Exp Pathol; 2015; 8(9):10283-93. PubMed ID: 26617736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
    Wikström P; Lindahl C; Bergh A
    Prostate; 2005 Feb; 62(2):148-64. PubMed ID: 15389804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen-independent prostate cancer progression in the TRAMP model.
    Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
    Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Divergent effects of castration on prostate cancer in TRAMP mice: possible implications for therapy.
    Tang Y; Wang L; Goloubeva O; Khan MA; Zhang B; Hussain A
    Clin Cancer Res; 2008 May; 14(10):2936-43. PubMed ID: 18483360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization against luteinizing hormone-releasing hormone fusion proteins does not decrease prostate cancer in the transgenic adenocarcinoma mouse prostate model.
    Hill RE; de Avila DM; Bertrand KP; Greenberg NM; Reeves JJ
    Exp Biol Med (Maywood); 2003 Jul; 228(7):818-22. PubMed ID: 12876301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model.
    Huss WJ; Gray DR; Tavakoli K; Marmillion ME; Durham LE; Johnson MA; Greenberg NM; Smith GJ
    Neoplasia; 2007 Nov; 9(11):938-50. PubMed ID: 18030362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-aza-2'-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer.
    Zorn CS; Wojno KJ; McCabe MT; Kuefer R; Gschwend JE; Day ML
    Clin Cancer Res; 2007 Apr; 13(7):2136-43. PubMed ID: 17404097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Castration triggers growth of previously static androgen-independent lesions in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
    Johnson MA; Iversen P; Schwier P; Corn AL; Sandusky G; Graff J; Neubauer BL
    Prostate; 2005 Mar; 62(4):322-38. PubMed ID: 15389779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
    Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
    Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TRAMP mouse as a model for prostate cancer.
    Hurwitz AA; Foster BA; Allison JP; Greenberg NM; Kwon ED
    Curr Protoc Immunol; 2001 Nov; Chapter 20():20.5.1-20.5.23. PubMed ID: 18432778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
    Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broadening of transgenic adenocarcinoma of the mouse prostate (TRAMP) model to represent late stage androgen depletion independent cancer.
    Jeet V; Ow K; Doherty E; Curley B; Russell PJ; Khatri A
    Prostate; 2008 Apr; 68(5):548-62. PubMed ID: 18247402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of castration on the development of prostate adenocarcinoma from its precursor HGPIN and on the occurrence of androgen-independent, poorly differentiated carcinoma in TRAMP mice.
    Bono AV; Montironi R; Pannellini T; Sasso F; Mirone V; Musiani P; Iezzi M
    Prostate Cancer Prostatic Dis; 2008; 11(4):377-83. PubMed ID: 18379588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early castration reduces prostatic carcinogenesis in transgenic mice.
    Eng MH; Charles LG; Ross BD; Chrisp CE; Pienta KJ; Greenberg NM; Hsu CX; Sanda MG
    Urology; 1999 Dec; 54(6):1112-9. PubMed ID: 10604719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early growth inhibition is followed by increased metastatic disease with vitamin D (calcitriol) treatment in the TRAMP model of prostate cancer.
    Ajibade AA; Kirk JS; Karasik E; Gillard B; Moser MT; Johnson CS; Trump DL; Foster BA
    PLoS One; 2014; 9(2):e89555. PubMed ID: 24586868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dietary tomato and lycopene impact androgen signaling- and carcinogenesis-related gene expression during early TRAMP prostate carcinogenesis.
    Wan L; Tan HL; Thomas-Ahner JM; Pearl DK; Erdman JW; Moran NE; Clinton SK
    Cancer Prev Res (Phila); 2014 Dec; 7(12):1228-39. PubMed ID: 25315431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of time of castration and tumour volume on time to androgen-independent recurrence in Shionogi tumours.
    So AI; Bowden M; Gleave M
    BJU Int; 2004 Apr; 93(6):845-50. PubMed ID: 15050003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β1 integrin deletion enhances progression of prostate cancer in the TRAMP mouse model.
    Moran-Jones K; Ledger A; Naylor MJ
    Sci Rep; 2012; 2():526. PubMed ID: 22829980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expansion of mouse castration-resistant intermediate prostate stem cells in vitro.
    Xu Y; Mu J; Zhou Z; Leng Y; Yu Y; Song X; Liu A; Zhu H; Li J; Wang D
    Stem Cell Res Ther; 2022 Jul; 13(1):299. PubMed ID: 35841025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.